Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -63.45% is 58% below its 3-year average of -40.05%, around the middle of its 3-year range (-92.97%–-11.77%).
As of the fiscal period ended Tuesday, June 30, 2026. 57.28% below its 12-month average of -40.34%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -63.45%.
RETURN ON EQUITY (ROE)
-63.45%
RETURN ON EQUITY (ROE) AVG TTM
-40.34%
RETURN ON EQUITY (ROE) AVG 3Y
-42.23%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-57.28%
CURRENT VS 3Y AVG
-50.27%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-51.04%
vs the sector median at left
Mineralys Therapeutics, Inc.
Market Cap
$1.94B
Return on Equity (ROE)
-63.45%
TTM Avg
-40.34%
3Y Avg
-42.23%
5Y Avg
N/A
Market Cap
$1.92B
Return on Equity (ROE)
-179.99%
TTM Avg
-188.10%
3Y Avg
28.98%
5Y Avg
-2.67%
Market Cap
$1.95B
Return on Equity (ROE)
-13.09%
TTM Avg
-10.89%
3Y Avg
-18.29%
5Y Avg
-19.41%
Market Cap
$1.96B
Return on Equity (ROE)
-25.62%
TTM Avg
-51.30%
3Y Avg
-29.11%
5Y Avg
-20.20%
Market Cap
$1.97B
Return on Equity (ROE)
16.36%
TTM Avg
13.19%
3Y Avg
3.41%
5Y Avg
-4.94%
Market Cap
$1.98B
Return on Equity (ROE)
-16.25%
TTM Avg
-99.56%
3Y Avg
-48.75%
5Y Avg
-32.00%
Market Cap
$1.89B
Return on Equity (ROE)
-40.09%
TTM Avg
4.56%
3Y Avg
-13.84%
5Y Avg
-2.18%
Market Cap
$1.89B
Return on Equity (ROE)
-186.63%
TTM Avg
-33.22%
3Y Avg
-16.69%
5Y Avg
-32.64%
Market Cap
$1.89B
Return on Equity (ROE)
12.01%
TTM Avg
-4.52%
3Y Avg
-16.89%
5Y Avg
-11.36%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.94B | -63.45% | -40.34% | -42.23% | N/A |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | -179.99% | -188.10% | 28.98% | -2.67% |
| AxoGen, Inc. (AXGN)vs › | $1.95B | -13.09% | -10.89% | -18.29% | -19.41% |
| Vir Biotechnology, Inc. (VIR)vs › | $1.96B | -25.62% | -51.30% | -29.11% | -20.20% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 16.36% | 13.19% | 3.41% | -4.94% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | -16.25% | -99.56% | -48.75% | -32.00% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | -40.09% | 4.56% | -13.84% | -2.18% |
| Zymeworks Inc. (ZYME)vs › | $1.89B | -186.63% | -33.22% | -16.69% | -32.64% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 12.01% | -4.52% | -16.89% | -11.36% |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | -15.90% | -35.70% | -33.44% | -75.43% |
ROE
-63.5%
ROA
-52.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -63.45% |
| 2026-03-31 | -23.78% |
| 2025-12-31 | -23.91% |
| 2025-09-30 | -29.73% |
| 2025-06-30 | -60.84% |
| 2025-03-31 | -55.19% |
| 2024-12-31 | -92.97% |
| 2024-09-30 | -64.68% |
| 2024-06-30 | -41.25% |
| 2024-03-31 | -27.68% |
| 2023-12-31 | -29.81% |
| 2023-09-30 | -21.43% |
| 2023-06-30 | -14.21% |
| 2023-03-31 | -11.77% |
